Stryker Corporation $SYK Shares Bought by River Wealth Advisors LLC

River Wealth Advisors LLC raised its stake in shares of Stryker Corporation (NYSE:SYK) by 7.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,350 shares of the medical technology company’s stock after purchasing an additional 2,048 shares during the period. Stryker accounts for 0.8% of River Wealth Advisors LLC’s holdings, making the stock its 29th biggest position. River Wealth Advisors LLC’s holdings in Stryker were worth $9,241,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new stake in Stryker in the 2nd quarter worth about $205,000. Marshall Wace LLP boosted its holdings in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in Stryker during the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC acquired a new position in shares of Stryker during the second quarter valued at approximately $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 0.7%

SYK opened at $338.80 on Friday. The firm has a market capitalization of $129.95 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The company’s 50 day simple moving average is $324.61 and its two-hundred day simple moving average is $333.57. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the prior year, the business earned $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SYK. Wells Fargo & Company decreased their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research report on Friday, May 1st. JPMorgan Chase & Co. reduced their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Piper Sandler decreased their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Citigroup reaffirmed a “buy” rating on shares of Stryker in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.